Neuronal ceroid lipofuscinoses

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1793, Issue 4, 2009, Pages 697-709

  Jalanko, Anu ^a   Braulke, Thomas ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Animal model; Lysosomal storage disease; Lysosome; NCL; Neurodegeneration

Indexed keywords

CEROID; MEMBRANE PROTEIN; PALMITOYL PROTEIN THIOESTERASE;

BRAIN CORTEX; CELL ACTIVATION; CEREBELLUM CORTEX; CLCN7 GENE; CLINICAL FEATURE; CLN1 GENE; CLN10 GENE; CLN2 GENE; CLN3 GENE; CLN4 GENE; CLN5 GENE; CLN6 GENE; CLN7 GENE; CLN8 GENE; CLN9 GENE; DEMENTIA; ENDOPLASMIC RETICULUM; ENDOSOME; EPILEPSY; GENE; GENE MUTATION; GLIA CELL; LYSOSOME; LYSOSOME STORAGE DISEASE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; PRIORITY JOURNAL; RETINOPATHY; REVIEW; THALAMOCORTICAL TRACT;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MEMBRANE PROTEINS; NEURONAL CEROID-LIPOFUSCINOSES;

ANIMALIA;

EID: 62949195147     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.11.004     Document Type: Review

References (228)

1. Haltia M. The neuronal ceroid lipofuscinoses: from past to present. Biochim. Biophys. Acta 1762 (2006) 850-856
2. Santavuori P. Neuronal ceroid-lipofuscinoses in childhood. Brain Dev. 10 (1988) 80-83
3. Siintola E., Lehesjoki A.-E., and Mole S.E. Molecular genetics of the NCLS - status and perspectives. Biochim. Biophys. Acta 1762 (2006) 857-864
4. Siintola E., Partanen S., Stromme P., Mehlen J., Haapanen A., Haltia M., Lehesjoki A.E., and Tyynelä J. Cathepsin D deficiency underlies congenital human neuronal ceroid lipofuscinosis. Brain 129 (2006) 1438-1445
5. Siintola E., Topcu M., Aula N., Lohi H., Minassian B.A., Paterson A.D., Liu X.Q., Wilson C., Lahtinen U., Anttonen A.K., and Lehesjoki A.-E. The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. Am. J. Hum. Genet. 81 (2007) 136-146
6. Steinfeld R., Reinhardt K., Schreiber K., Hillebrand M., Kraetzner R., Brück W., Saftig P., and Gärtner J. Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am. J. Hum. Genet. 78 (2006) 988-998
7. Jentsch T.J. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit. Rev. Biochem. Mol. Biol. 43 (2008) 3-36
8. Haltia M. The neuronal ceroid-lipofuscinoses. J. Neuropathol. Exp. Neurol. 62 (2003) 1-13
9. Williams R.E., Åberg L., Autti T., Goebel H.H., Kohlschütter A., and Lönnqvist T. Diagnosis of the neuronal ceroid lipofuscinoses: an update. Biochim. Biophys. Acta 1762 (2006) 865-872
10. Goebel H.H., Mole S., and Lake B.D. The Neuronal Ceroid Lipofuscinoses (Batten Disease) (1999), IOS Press, Amsterdam 1-197
11. Mole S.E., Williams R.E., and Goebel H.H. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 6 (2005) 107-126
12. Futerman A.H., and van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev., Mol. Cell Biol. 5 (2004) 554-565
13. Kyttälä A., Lahtinen U., Braulke T., and Hofmann S.L. Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins. Biochim. Biophys. Acta 1762 (2006) 920-933
14. Tyynelä J., Palmer D.N., Baumann M., and Haltia M. Storage of saposins A and D in infantile neuronal ceroid-lipofuscinosis. FEBS Lett. 330 (1993) 8-12
15. Elleder M., Sokolova J., and Hrebicek M. Acta Neuropathol. 93 (1997) 379-390
16. Jalanko A., Tyynelä J., and Peltonen L. From genes to systems: new global strategies for the characterization of NCL biology. Biochim. Biophys. Acta 1762 (2006) 934-944
17. Cooper J.D., Russell C., and Mitchison H.M. Progress towards understanding disease mechanisms in small vertebrate models of neuronal ceroid lipofuscinosis. Biochim. Biophys. Acta 1762 (2006) 873-889
18. Phillips S.N., Muzaffar N., Codlin S., Korey C.A., Taschner P.E.M., de Voer G., Mole S.E., and Pearce D.A. Characterizing pathogenic processes in Batten disease: use of small eukaryotic model systems. Biochim. Biophys. Acta 1762 (2006) 906-919
19. Vesa J., Hellsten E., Verkruyse L.A., Camp L.A., Rapola J., Santavuori P., Hofmann S.L., and Peltonen L. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 376 (1995) 584-587
20. Camp L.A., and Hofmann S.L. Purification and properties of a palmitoyl-protein thioesterase that cleaves palmitate from H-Ras. J. Biol. Chem. 268 (1993) 22566-22574
21. Verkruyse L.A., and Hofmann S.L. Lysosomal targeting of palmitoyl-protein thioesterase. J. Biol. Chem. 271 (1996) 15831-15836
22. Bellizzi III J.J., Widom J., Kemp C., Lu J.Y., Das A.K., Hofmann S.L., and Clardy J. The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4573-4578
23. Hellsten E., Vesa J., Olkkonen V.M., Jalanko A., and Peltonen L. Human palmitoyl protein thioesterase: evidence for lysosomal targeting of the enzyme and disturbed cellular routing in infantile neuronal ceroid lipofuscinosis. EMBO J. 15 (1996) 5240-5245
24. Sleat D.E., Lackland H., Wang Y., Sohar I., Xiao G., Li H., and Lobel P. The human brain mannose 6-phosphate glycoproteome: a complex mixture composed of multiple isoforms of many soluble lysosomal proteins. Proteomics 5 (2005) 1520-1532
25. Virmani T., Gupta P., Liu X., Kavalali E.T., and Hofmann S.L. Progressively reduced synaptic vesicle pool size in cultured neurons derived from neuronal ceroid lipofuscinosis-1 knockout mice. Neurobiol. Dis. 20 (2005) 314-323
26. Isosomppi J., Heinonen O., Hiltunen J.O., Greene N.D., Vesa J., Uusitalo A., Mitchisone H.M., Saarma M., Jalanko A., and Peltonen L. Developmental expression of palmitoyl protein thioesterase in normal mice. Brain Res. Dev. Brain Res. 118 (1999) 1-11
27. Heinonen O., Kyttala A., Lehmus E., Paunio T., Peltonen L., and Jalanko A. Expression of palmitoyl protein thioesterase in neurons. Mol. Genet. Metab. 69 (2000) 123-129
28. Lehtovirta M., Kyttälä A., Eskelinen E.L., Hess M., Heinonen O., and Jalanko A. Palmitoyl protein thioesterase (PPT) localizes into synaptosomes and synaptic vesicles in neurons: implications for infantile neuronal ceroid lipofuscinosis (INCL). Hum. Mol. Genet. 10 (2001) 69-75
29. Suopanki J., Lintunen M., Lahtinen H., Haltia M., Panula P., Baumann M., and Tyynelä J. Status epilepticus induces changes in the expression and localization of endogenous palmitoyl-protein thioesterase 1. Neurobiol. Dis. 10 (2002) 247-257
30. Ahtiainen L., van Diggelen O.P., Jalanko A., and Kopra O. Palmitoyl protein thioesterase 1 is targeted to the axons in neurons. J. Comp. Neurol. 455 (2003) 368-377
31. Lyly A., von Schantz C., Saloanen T., Kopra O., Saarela J., Jauhiainen M., Kyttälä A., and Jalanko A. BMC Cell Biol. 8 (2007) 22
32. Goswami R., Ahmed M., Kilkus J., Han T., Dawson S.A., and Dawson G. Differential regulation of ceramide in lipid-rich microdomains (rafts): antagonistic role of palmitoyl:protein thioesterase and neutral sphingomyelinase 2. J. Neurosci. Res. 81 (2005) 208-217
33. Huang K., and El-Husseini A. Modulation of neuronal protein trafficking and function by palmitoylation. Curr. Opin. Neurobiol 15 (2005) 527-535
34. Cho S., and Dawson G. Palmitoyl protein thioesterase 1 protects against apoptosis mediated by Ras-Akt-caspase pathway in neuroblastoma cells. J. Neurochem. 74 (2000) 1478-1488
35. Cho S., Dawson P.E., and Dawson G. Antisense palmitoyl protein thioesterase 1 (PPT1) treatment inhibits PPT1 activity and increases cell death in LA-N-5 neuroblastoma cells. J. Neurosci. Res. 62 (2000) 234-240
36. Zhang Z., Lee Y.C., Kim S.J., Choi M.S., Tsai P.C., Xu Y., Xiao Y.J., Zhang P., Heffer A., and Mukherjee A.B. Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL. Hum. Mol. Genet. 15 (2006) 337-346
37. Holopainen J.M., Saarikoski J., Kinnunen P.K., and Jarvela I. Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). Eur. J. Biochem. 268 (2001) 5851-5856
38. Ahtiainen L., Luiro K., Kauppi M., Tyynelä J., Kopra O., and Jalanko A. Palmitoyl protein thioesterase 1 (PPT1) deficiency causes endocytic defects connected to abnormal saposin processing. Exp. Cell Res. 312 (2006) 1540-1553
39. Lyly A., Marjavaara S.K., Kyttälä A., Uusi-Rauva K., Luiro K., Kopra O., Martinez L.O., Tanhuanpää K., Kalkkinen N., Suomalainen A., Jauhiainen M., and Jalanko A. Deficiency of the INCL protein (palmitoyl protein thioesterase 1) results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism. Hum. Mol. Genet. 17 (2008) 1406-1417
40. Das A.K., Becerra C.H., Yi W., Lu J.Y., Siakotos A.N., Wisniewski K.E., and Hofmann S.L. Molecular genetics of palmitoyl-protein thioesterase deficiency in the U.S. J. Clin. Invest. 102 (1998) 361-370
41. Mitchison H.M., Hofmann S.L., Becerra C.H., Munroe P.B., Lake B.D., Crow Y.J., Stephenson J.B., Williams R.E., Hofman I.L., Taschner P.E., Martin J.J., Philippart M., Andermann E., Andermann F., Mole S.E., Gardiner R.M., and O'Rawe A.M. Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits. Hum. Mol. Genet. 7 (1998) 291-297
42. van Diggelen O.P., Thobois S., Tilikete C., Zabot M.T., Keulemans J.L., van Bunderen P.A., Taschner P.E., Losekoot M., and Voznyi Y.V. Adult neuronal ceroid lipofuscinosis with palmitoyl-protein thioesterase deficiency: first adult-onset patients of a childhood disease. Ann. Neurol. 50 (2001) 269-272
43. Gupta P., Soyombo A.A., Atashband A., Wisniewski K.E., Shelton J.M., Richardson J.A., Hammer R.E., and Hofmann S.L. Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13566-13571
44. Jalanko A., Vesa J., Manninen T., von Schantz C., Minye H., Fabritius A.L., Salonen T., Rapola J., Gentile M., Kopra O., and Peltonen L. Mice with Ppt1Deltaex4 mutation replicate the INCL phenotype and show an inflammation-associated loss of interneurons. Neurobiol. Dis. 18 (2005) 226-241
45. Bible E., Gupta P., Hofmann S.L., and Cooper J.D. Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16 (2004) 346-359
46. Kielar C., Maddox L., Bible E., Pontikis C.C., Macauley S.L., Griffey M.A., Wong M., Sands M.S., and Cooper J.D. Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 25 (2007) 150-162
47. Elshatory Y., Brooks A.I., Chattopadhyay S., Curran T.M., Gupta P., Ramalingam V., Hofmann S.L., and Pearce D.A. Early changes in gene expression in two models of Batten disease. FEBS Lett. 538 (2003) 207-212
48. von Schantz C., Saharinen J., Kopra O., Cooper J., Gentile M., Hovatta I., Peltonen L., and Jalanko A. Brain gene expression profiles of Cln1 and Cln5 deficient mice unravel common molecular pathways underlying neuronal ceroid lipofuscinosis. BMC Genomics 9 (2008) 146
49. Das A.M., Jolly R.D., and Kohlschütter A. Anomalies of mitochondrial ATP synthase regulation in four different types of neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 66 (1999) 349-355
50. Cho S., Dawson P.E., and Dawson G. Role of palmitoyl-protein thioesterase in cell death: implications for infantile neuronal ceroid lipofuscinosis. Eur. J. Paediatr. Neurol. 5 Suppl A (2001) 53-55
51. Käkelä R., Somerharju P., and Tyynelä J. Analysis of phospholipid molecular species in brains from patients with infantile and juvenile neuronal-ceroid lipofuscinosis using liquid chromatography-electrospray ionization mass spectrometry. J. Neurochem. 84 (2003) 1051-1065
52. Ahtiainen L., Kolikova J., Mutka A.L., Luiro K., Gentile M., Ikonen E., Khiroug L., Jalanko A., and Kopra O. Palmitoyl protein thioesterase 1 (Ppt1)-deficient mouse neurons show alterations in cholesterol metabolism and calcium homeostasis prior to synaptic dysfunction. Neurobiol. Dis. 28 (2007) 52-64
53. Kim S.J., Zhang Z., Hitomi E., Lee Y.C., and Mukherjee A.B. Endoplasmic reticulum stress-induced caspase-4 activation mediates apoptosis and neurodegeneration in INCL. Hum. Mol. Genet. 15 (2006) 1826-1834
54. Hermansson M., Käkelä R., Berghall M., Lehesjoki A.E., Somerharju P., and Lahtinen U. Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation, EPMR, brain: a case study. J. Neurochem. 95 (2005) 609-617
55. Granier L.A., Langley K., Leray C., and Sarlieve L.L. Phospholipid composition in late infantile neuronal ceroid lipofuscinosis. Eur. J. Clin. Invest. 30 (2000) 1011-1017
56. Griffey M., Macauley S.L., Ogilvie J.M., and Sands M.S. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Molec. Ther. 12 (2005) 413-421
57. Griffey M.A., Wozniak D., Wong M., Bible E., Johnson K., Rothman S.M., Wentz A.E., Cooper J.D., and Sands M.S. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Molec. Ther. 13 (2006) 538-547
58. Porter M.Y., Turmaine M., and Mole S.E. Identification and characterization of Caenorhabditis elegans palmitoyl protein thioesterase1. J. Neurosci. Res. 79 (2005) 836-848
59. Hickey A.J., Chotkowski H.L., Singh N., Ault J.G., Korey C.A., McDonald M.E., and Glaser R.L. Palmitoyl protein thioesterase deficiency in Drosophila melanogaster causes accumulation of abnormal storage material and reduced life span. Genetics 172 (2006) 2379-2390
60. Sleat D.E., Donnelly R.J., Lackland H., Liu C.G., Sohar I., Pullarkat R.K., and Lobel P. Association of mutations in a lysosomal protein with classical late infantile neuronal ceroid lipofuscinosis. Science 277 (1997) 1802-1805
61. Golabek A.A., and Kida E. Tripeptidyl peptidase I in health and disease. Biol. Chem. 387 (2006) 1091-1099
62. Junaid M.A., and Pullarkat R.K. Increased brain lysosomal pepstatin-insensitive proteinase activity in patients with neurodegenerative diseases. Neurosci. Lett. 264 (1999) 157-160
63. Vesa J., Chin M.H., Oelgeschlager K., Isosomppi J., DellAngelica E.C., Jalanko A., and Peltonen L. Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein with CLN2 and CLN3. Mol. Biol. Cell 13 (2002) 2410-2420
64. Golabek A.A., Kida E., Walus M., Wujek P., Mehta P., and Wisniewski K.E. Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I. J. Biol. Chem. 278 (2003) 7135-7145
65. Golabek A.A., Wujek P., Walus M., Bieler S., Soto C., Wisniewski K.E., and Kida E. Maturation of human tripeptidyl-peptidase I in vitro. J. Biol. Chem. 279 (2004) 31058-31067
66. Wujek P., Kida E., Walus M., Wisniewski K.E., and Golabek A.A. N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl-peptidase I. J. Biol. Chem. 279 (2004) 12827-12839
67. Chang M., Cooper J.D., Sleat D.E., Cheng S.H., Dodge J.D., Passini M.A., Lobel P., and Davidson B.L. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Molec. Ther. 16 (2008) 649-656
68. Wlodawer A., Durell S.R., Li M., Oyama H., Oda K., and Dunn B.M. A model of tripeptidyl-peptidase I (CLN2), a ubiquitous and highly conserved member of the sedolisin family of serine-carboxyl peptidases. BMC Struct. Biol. 3 (2003) 8
69. Lin L., Sohar I., Lackland H., and Lobel P. The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH. J. Biol. Chem. 276 (2001) 2249-2255
70. Walus M., Kida E., Wisniewski K.E., and Golabek A.A. Ser475, Glu272, Asp276, Asp327, and Asp360 are involved in catalytic activity of human tripeptidyl-peptidase I. FEBS Lett. 579 (2005) 1383-1388
71. Ezaki J., Tanida I., Kanehagi N., and Kominami E. A lysosomal proteinase, the late infantile neuronal ceroid lipofuscinosis gene (CLN2) product, is essential for degradation of a hydrophobic protein, the subunit c of ATP synthase. J. Neurochem. 72 (1999) 2573-2582
72. Junaid M.A., Wu G., and Pullarkat R.K. Purification and characterization of bovine brain lysosomal pepstatin-insensitive proteinase, the gene product deficient in the human late-infantile neuronal ceroid lipofuscinosis. J Neurochem. 74 (2000) 287-294
73. Kopan S., Sivasubramaniam U., and Warburton M.J. The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis. Biochem. Biophys. Res. Commun. 319 (2004) 58-65
74. Wisniewski K.E., and Zhong N. Batten Disease: Diagnosis, Treatment and Research (2001), Academic Press, San Diego 1-243
75. Kohlschütter A., Gardiner R.M., and Goebel H.H. Human forms of neuronal ceroid lipofuscinosis (Batten disease): consensus on diagnostic criteria. J. Inherited Metab. Dis. 16 (1993) 241-244
76. Palmer D.N., Fearnley I.M., Walker J.E., Hall N.A., Lake B.D., Wolfe L.S., Haltia M., Martinus R.D., and Jolly R.D. Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease). Am. J. Med. Genet. 42 (1992) 561-567
77. Sleat D.E., Wiseman J.A., El-Banna M., Kim K.H., Mao Q., Price S., Macauley S.L., Sidman R.L., Shen M.M., Zhao Q., Passini M.A., Davidson B.L., Stewart G.R., and Lobel P. A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J. Neurosci. 24 (2004) 9117-9126
78. Awano T., Katz M.L., O'Brien D.P., Sohar I., Lobel P., Coates J.R., Khan S., Johnson G.C., Giger U., and Johnson G.S. A frame shift mutation in canine TPP1 (the ortholog of human CLN2) in a juvenile Dachshund with neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 89 (2006) 254-260
79. Passini M.A., Dodge J.C., Bu J., Yang W., Zhao Q., Sondhi D., Hackett N.R., Kaminsky S.M., Mao Q., Shihabuddin L.S., Cheng S.H., Sleat D.E., Stewart G.R., Davidson B.L., Lobel P., and Crystal R.G. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J. Neurosci. 26 (2006) 1334-1342
80. Cabrera-Salazar M.A., Rodkelley E.M., Bu J., Hodges B.L., Yew N., Dodge J.C., Shihabuddin L.S., Sohar I., Sleat D.E., Scheule R.K., Davidson B.L., Cheng S.H., Lobel P., and Passini M.A. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile Batten disease. Molec. Ther. 15 (2007) 1782-1788
81. Sondhi D., Hackett N.R., Peterson D.A., Stratton J., Bead M., Travis K.M., Wilson J.M., and Crystal R.G. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Molec. Ther. 15 (2007) 481-491
82. Worgall S., Sondhi D., Hackett N.R., Kosofsky B., Kekatpure M.V., Neyzi N., Dyke J.P., Ballon D., Heier L., Greenwald B.M., Christos P., Mazumdar M., Souweidane M.M., Kaplitt M.G., and Crystal R.G. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19 (2008) 463-474
83. The International Batten Disease Consortium. Isolation of a novel gene underlying Batten disease, CLN3. Cell 82 (1995) 949-957
84. Ezaki J., Takeda-Ezaki M., Koike M., Ohsawa Y., Taka H., Mineki R., Murayama K., Uchiyama Y., Ueno T., and Kominami E. Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein. J. Neurochem. 87 (2003) 1296-1308
85. Kyttälä A., Ihrke G., Vesa J., Schell M.J., and Luzio J.P. Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. Mol. Biol. Cell 15 (2004) 1313-1323
86. Storch S., Pohl S., Quitsch A., Falley K., and Braulke T. C-terminal prenylation of the CLN3 membrane glycoprotein is requires for efficient endosomal sorting to lysosomes. Traffic 8 (2007) 431-444
87. Nugent T., Mole S.E., and Jones D.T. The transmembrane topology of Batten disease protein CLN3 determined by consensus computational prediction constrained by experimental data. FEBS Lett. 582 (2008) 1019-1024
88. Jarvela I., Sainio M., Rantamaki T., Olkkonen V.M., Carpen O., Peltonen L., and Jalanko A. Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease. Hum. Mol. Genet. 7 (1998) 85-90
89. Luiro K., Kopra O., Lehtovirta M., and Jalanko A. CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease. Hum. Mol. Genet. 10 (2001) 2123-2131
90. Mao Q., Foster B.J., Xia H., and Davidson B.L. Membrane topology of CLN3, the protein underlying Batten disease. FEBS Lett. 541 (2003) 40-46
91. Persaud-Sawin D.A., McNamara II J.O., Rylova S., Vandongen A., and Boustany R.M. A galactosylceramide binding domain is involved in trafficking of CLN3 from Golgi to rafts via recycling endosomes. Pediatr. Res. 56 (2004) 449-463
92. Rakheja D., Narayan S.B., Pastor J.V., and Bennett M.J. CLN3P, the Batten disease protein, localizes to membrane lipid rafts (detergent-resistant membranes). Biochem. Biophys. Res. Commun. 317 (2004) 988-991
93. Storch S., Pohl S., and Braulke T. A dileucine motif and a cluster of acidic amino acids in the second cytoplasmic domain of the Batten disease-related CLN3 protein are required for efficient lysosomal targeting. J. Biol. Chem. 279 (2004) 53625-53634
94. Kyttälä A., Yliannala K., Schu P., Jalanko A., and Luzio J.P. AP-1 and AP-3 facilitate lysosomal targeting of Batten disease protein CLN3 via its dileucine motif. J. Biol. Chem. 280 (2005) 10277-10283
95. Pearce D.A., and Sherman F. A yeast model for the study of Batten disease. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6915-6918
96. Pearce D.A., Ferea T., Nosel S.A., Das B., and Sherman F. Action of BTN1, the yeast orthologue of the gene mutated in Batten disease. Nat. Genet. 22 (1999) 55-58
97. Gachet Y., Codlin S., Hyams J.S., and Mole S.E. btn1, the Schizosaccharomyces pombe homologue of the human Batten disease gene CLN3, regulates vacuole homeostasis. J. Cell. Sci. 118 (2005) 5525-5536
98. Padilla-Lopez S., and Pearce D.A. Saccharomyces cerevisiae lacking Btn1p modulate vacuolar ATPase activity in order to regulate pH imbalance in the vacuole. J. Biol. Chem. 281 (2006) 10273-10280
99. Kim Y., Ramirez-Montealegre D., and Pearce D.A. Arole in vacuolar arginine transport for yeast Btn1p and for human CLN3, the protein defective in Batten disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15458-15462
100. Ramirez-Montealegre D., and Pearce D.A. Defective lysosomal arginine transport in juvenile Batten disease. Hum. Mol. Genet. 14 (2005) 3759-3773
101. Pearce D.A., McCall K., Mooney R.A., Chattopadhyay S., and Curran T.M. Altered amino acid levels in sera of a mouse model for juvenile neuronal ceroid lipofuscinoses. Clin. Chim. Acta 332 (2003) 145-148
102. Codlin S., Haines R.L., and Mole S.E. btn1 affects endocytosis, polarization of sterol-rich membrane domains and polarized growth in Schizosaccharomyces pombe. Traffic 9 (2008) 936-950
103. Luiro K., Yliannala K., Ahtiainen L., Maunu H., Jarvela I., Kyttälä A., and Jalanko A. Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway. Hum. Mol. Genet. 13 (2004) 3017-3027
104. Kitzmuller C., Haines R.L., Codlin S., Cutler D.F., and Mole S.E. A function retained by the common mutant CLN3 protein is responsible for the late onset of juvenile neuronal ceroid lipofuscinosis. Hum. Mol. Genet. 17 (2008) 303-312
105. Richardson S.C., Winistorfer S.C., Poupon V., Luzio J.P., and Piper R.C. Mammalian late vacuole protein sorting orthologues participate in early endosomal fusion and interact with the cytoskeleton. Mol. Biol. Cell 15 (2004) 1197-1210
106. Kama R., Robinson M., and Gerst J.E. Btn2, a Hook1 ortholog and potential Batten disease-related protein, mediates late endosome-Golgi protein sorting in yeast. Mol. Cell. Biol. 27 (2007) 605-621
107. Fossale E., Wolf P., Espinola J.A., Lubicz-Nawrocka T., Teed A.M., Gao H., Rigamonti D., Cattaneo E., MacDonald M.E., and Cotman S.L. Membrane trafficking and mitochondrial abnormalities precede subunit c deposition in a cerebellar cell model of juvenile neuronal ceroid lipofuscinosis. BMC Neurosci. 5 (2004) 57
108. Cao Y., Espinola J.A., FOssale E., Massey A.C., Cuervo A.M., Mc Donald M.E., and Cotman S.L. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J. Biol. Chem. 281 (2006) 20483-20493
109. Luiro K., Kopra O., Blom T., Gentile M., Mitchison H.M., Hovatta I., Tornquist K., and Jalanko A. Batten disease (JNCL) is linked to disturbances in mitochondrial, cytoskeletal, and synaptic compartments. J Neurosci Res 84 (2006) 1124-1138
110. Weimer J.M., Custer A.W., Benedict J.W., Alexander N.A., Kingsley E., Federoff H.J., Cooper J.D., and Pearce D.A. Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol. Dis. 22 (2006) 284-293
111. Brooks A.I., Chattopadhyay S., Mitchison H.M., Nussbaum R.L., and Pearce D.A. Functional categorization of gene expression changes in the cerebellum of a Cln3-knockout mouse model for Batten disease. Mol Genet Metab 78 (2003) 17-30
112. + ATPase complex, Exp. Cell Res. 314 (2008) 2895--2905.
113. Lane S.C., Jolly R.D., Schmechel D.E., Alroy J., and Boustany R.M. Apoptosis as the mechanism of neurodegeneration in Batten's disease. J. Neurochem. 67 (1996) 677-683
114. Seigel G.M., Lotery A., Kummer A., Bernard D.J., Greene N.D., Turmaine M., Derksen T., Nussbaum R.L., Davidson B., Wagner J., and Mitchison H.M. Retinal pathology and function in a Cln3 knockout mouse model of juvenile neuronal ceroid lipofuscinosis (Batten disease). Mol. Cell. Neurosci. 19 (2002) 515-527
115. Persaud-Sawin D.A., and Boustany R.M. Cell death pathways in juvenile Batten disease. Apoptosis 10 (2005) 973-985
116. Puranam K.L., Guo W.X., Qian W.H., Nikbakht K., and Boustany R.M. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol. Genet. Metab. 66 (1999) 294-308
117. Narayan S.B., Rakheja D., Tan L., Pastor J.V., and Bennett M.J. CLN3P, the Batten's disease protein, is a novel palmitoyl-protein Delta-9 desaturase. Ann. Neurol. 60 (2006) 570-577
118. Chang J.W., Choi H., Kim H.J., Jo D.G., Jeon Y.J., Noh J.Y., Park W.J., and Jung Y.K. Neuronal vulnerability of CLN3 deletion to calcium-induced cytotoxicity is mediated by calsenilin. Hum. Mol. Genet. 16 (2007) 317-326
119. Järvelä I., Lehtovirta M., Tikkanen R., Kyttälä A., and Jalanko A. Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum. Mol. Genet. 8 (1999) 1091-1098
120. Haskell R.E., Carr C.J., Pearce D.A., Bennett M.J., and Davidson B.L. Batten disease: evaluation of CLN3 mutations on protein localization and function. Hum. Mol. Genet. 9 (2000) 735-744
121. Carpenter S., Karpati G., and Andermann F. The ultrastructure characteristics of the abnormal cytosomes in Batten-Kufs' disease. Brain 100 (1977) 137-156
122. Mitchison H.M., Bernard D.J., Greene N.D., Cooper J.D., Junaid M.A., Pullarkat R.K., de Vos N., Breuning M.H., Owens J.W., Mobley W.C., Gardiner R.M., Lake B.D., Taschner P.E., and Nussbaum R.L. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]. Neurobiol. Dis. 6 (1999) 321-334
123. Cotman S.L., Vrbanac V., Lebel L.A., Lee R.L., Johnson K.A., Donahue L.R., Teed A.M., Antonellis K., Bronson R.T., Lerner T.J., and MacDonald M.E. Cln3(Deltaex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum Mol Genet 11 (2002) 2709-2721
124. Katz M.L., Shibuya H., Liu P.C., Kaur S., Cao C.L., and Johnson G.S. A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease). J. Neurosci. Res. 57 (1999) 551-556
125. Eliason S.L., Stein C.S., Mao Q., Tecedor L., Ding S.L., Gaines D.M., and Davidson B.L. A knock-in reporter model of Batten disease. J. Neurosci. 27 (2007) 9826-9834
126. Herrmann P., Druckrey-Fiskaaen C., Kouznetsova E., Heinittz K., Bigl M., Cotman S.L., and Schliebs R. Developmental impairments of select neurotransmitter systems in brains of Cln3(Deltaex7/8) knock-in mice, an animal model of juvenile neuronal ceroid lipofuscinosis. J. Neurosci. Res. 86 (2008) 1857-1870
127. Katz M.L., Johnson G.S., Tullis G.E., and Lei B. Phenotypic characterization of a mouse model of juvenile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 29 (2008) 242-253
128. Pontikis C.C., Cella C.V., Parihar N., Lim M.J., Chakrabarti S., Mitchison H.M., Mobley W.C., Rezaie P., Pearce D.A., and Cooper J.D. Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res 1023 (2004) 231-242
129. Pontikis C.C., Cotman S.L., MacDonald M.E., and Cooper J.D. Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model of Batten disease. Neurobiol. Dis. 20 (2005) 823-836
130. Chattopadhyay S., Ito M., Cooper J.D., Brooks A.I., Curran T.M., Powers J.M., and Pearce D.A. An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum. Mol. Genet. 11 (2002) 1421-1431
131. Castaneda J.A., and Pearce D.A. Identification of alpha-fetoprotein as an autoantigen in juvenile Batten disease. Neurobiol. Dis. 29 (2008) 92-102
132. Lim M.J., Alexander N., Benedict J.W., Chattopadhyay S., Shemilt S.J.A., Guérin C.J., Cooper J.D., and Pearce D.A. IgG entry and deposition are components of the neuroimmune response in Batten disease. Neurobiol. Dis. 25 (2007) 239-251
133. Kovacs A.D., and Pearce D.A. Attenuation of AMPA receptor activity improves motor skills in a mouse model of juvenile Batten disease. Exp. Neurol. 209 (2008) 288-291
134. Cooper J.D. Moving towards therapies for juvenile Batten disease ?. Exp. Neurol. 211 (2008) 329-331
135. de Voer G., van der Bent P., Rodrigues A.J., van Ommen G.J., Peters D.J., and Taschner P.E. Deletion of the Caenorhabditis elegans homologues of the CLN3 gene, involved in human juvenile neuronal ceroid lipofuscinosis, causes a mild progeric phenotype. J. Inherit. Metab. Dis. 28 (2005) 1065-1080
136. Savukoski M., Klockars T., Holmberg V., Santavuori P., Lander E.S., and Peltonen L. CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis. Nat. Genet. 19 (1998) 286-288
137. Isosomppi J., Vesa J., Jalanko A., and Peltonen L. Lysosomal localization of the neuronal ceroid lipofuscinosis CLN5 protein. Hum. Mol. Genet. 11 (2002) 885-891
138. Bessa C., Teixeira C.A., Mangas M., Dias A., Sá Miranda M.C., Guimãraes A., Ferreira J.C., Canas N., Cabral P., and Ribeiro M.G. Two novel CLN5 mutations in a Portuguese patient with vLINCL: insights into molecular mechanisms of CLN5 deficiency. Mol. Gen. Metab. 89 (2006) 245-253
139. Sleat D.E., Zheng H., Qian M., and Lobel P. Identification of sites of mannose 6-phosphorylation on lysosomal proteins. Mol. Cell. Proteomics 5 (2006) 686-701
140. Holmberg V., Jalanko A., Isosomppi J., Fabritius A.L., Peltonen L., and Kopra O. The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a soluble lysosomal glycoprotein expressed in the developing brain. Neurobiol. Dis. 16 (2004) 29-40
141. Holmberg V., Lauronen L., Autti T., Santavuori P., Savukoski M., Uvebrant P., Hofman I., Peltonen L., and Jarvela I. Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5). Neurology 55 (2000) 579-581
142. Pineda-Trujillo N., Cornejo W., Carrizosa J., Wheeler R.B., Munera S., Valencia A., Agudelo-Arango J., Cogollo A., Anderson G., Bedoya G., Mole S.E., and Ruiz-Linares A. A CLN5 mutation causing an atypical neuronal ceroid lipofuscinosis of juvenile onset. Neurology 64 (2005) 740-742
143. Cannelli N., Nardocci N., Cassandrini D., Morbin M., Aiello C., Bugiani M., Criscuolo L., Zara F., Striano P., Granata T., Bertini E., Simonati A., and Santorelli F.M. Revelation of a novel CLN5 mutation in early juvenile neuronal ceroid lipofuscinosis. Neuropediatrics 38 (2007) 46-49
144. Santavuori P., Rapola J., Nuutila A., Raininko R., Lappi M., Launes J., Herva R., and Sainio K. The spectrum of Jansky-Bielschowsky disease. Neuropediatrics 22 (1991) 92-96
145. Santavuori P., Rapola J., Sainio K., and Raitta C. A variant of Jansky-Bielschowsky disease. Neuropediatrics 13 (1982) 135-141
146. Tyynelä J., Suopanki J., Santavuori P., Baumann M., and Haltia M. Variant late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry. J. Neuropathol. Exp. Neurol. 56 (1997) 369-375
147. Kopra O., Vesa J., von Schantz C., Manninen T., Minye H., Fabritius A.L., Rapola J., van Diggelen O.P., Saarela J., Jalanko A., and Peltonen L. A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging. Hum. Mol. Genet. 13 (2004) 2893-2906
148. Melville S.A., Wilson C.L., Chiang C.S., Studdert V.P., Lingaas F., and Wilton A.N. A mutation in canine CLN5 causes neuronal ceroid lipofuscinosis in Border collie dogs. Genomics 86 (2005) 287-294
149. Houweling P.J., Cavanagh J.A., Palmer D.N., Frugier T., Mitchell N.L., Windsor P.A., Raadsma H.W., and Tammen I. Neuronal ceroid lipofuscinosis in Devon cattle is caused by a single base duplication (c.662dupG) in the bovine CLN5 gene. Biochim. Biophys. Acta 1762 (2006) 890-897
150. Frugier T., Mitchell N.L., Tammen I., Houweling P.J., Arthur D.G., Kay G.W., van Diggelen O.P., Jolly R.D., and Palmer D.N. A new large animal model of CLN5 neuronal ceroid lipofuscinosis in Borderdale sheep is caused by a nucleotide substitution at a consensus splice site (c.571+1G > A) leading to excision of exon 3. Neurobiol. Dis. 29 (2008) 306-315
151. Gao H., Boustany R.M., Espinola J.A., Cotman S.L., Srinidhi L., Antonellis K.A., Gillis T., Qin X., Liu S., Donahue L.R., Bronson R.T., Faust J.R., Stout D., Haines J.L., Lerner T.J., and MacDonald M.E. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am. J. Hum. Genet. 70 (2002) 324-335
152. Wheeler R.B., Sharp J.D., Schultz R.A., Joslin J.M., Williams R.E., and Mole S.E. The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. Am. J. Hum. Genet. 70 (2002) 537-542
153. Heine C., Koch B., Storch S., Kohlschutter A., Palmer D.N., and Braulke T. Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A. J. Biol. Chem. 279 (2004) 22347-22352
154. Mole S.E., Michaux G., Codlin S., Wheeler R.B., Sharp J.D., and Cutler D.F. CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein. Exp. Cell Res. 298 (2004) 399-406
155. Heine C., Quitsch A., Storch S., Martin Y., Lonka L., Lehesjoki A.-E., Mole S.-E., and Braulke T. Topology and endoplasmic reticulum retention signals of the lysosomal storage disease-related membrane protein CLN6. Mol. Membr. Biol. 24 (2007) 74-87
156. Sharp J., Wheeler R., Parker K., Gardiner M., Williams R., and Mole S. Spectrum of CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis. Hum. Mutat. 22 (2003) 35-42
157. Siintola E., Topcu M., Kohlschütter A., Salonen T., Joensuu T., Anttonen A., and Lehesjoki A. Two novel CLN6 mutations in variant late-infantile neuronal ceroid lipofuscinosis patients of Turkish origin. Clin. Genet. 68 (2005) 167-173
158. Jolly R., Shimada A., Dopfmer I., Slack P.M., Birtles P.M., and Palmer D.N. Ceroid-lipofuscinosis (Batten's disease): pathogenesis and sequential neuropathological changes in the ovine model. Neuropathol. Appl. Neurobiol. 15 (1989) 371-383
159. Bronson R.T., Donahue L.R., Johnson K.R., Tanner A., Lane P.W., and Faust J.R. Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. Am. J. Med. Genet. 77 (1998) 289-297
160. Tammen I., Houweling P., Frugier T., Mitchell N., Kay G., Cavanagh J., Cook R., Raadsma H., and Palmer D. A missense mutation (c.184C > T) in ovine CLN6 causes neuronal ceroid lipofuscinosis in Merino sheep whereas affected South Hampshire sheep have reduced levels of CLN6 mRNA. Biochim. Biophys. Acta 1762 (2006) 898-905
161. S. Jabs, A. Quitsch, R. Käkelä, B. Koch, J. Tyynelä, H. Brade, M. Glatzel, S.U. Walkley, P. Saftig, M.T. Vanier, T. Braulke, Accumulation of bis(monoacylglycero)phosphate and gangliosides in mouse models of neuronal ceroid lipofuscinosis, J. Neurochem. 106 (2008) 1415--1425.
162. Broom M., Zhou C., Je B., Barwell K., Jolly R., and Hill D. Ovine neuronal ceroid lipofuscinosis: a large animal model syntenic with the human neuronal ceroid lipofuscinosis variant CLN6. J. Med. Genet. 35 (1998) 717-721
163. Oswald M.J., Palmer D.N., Kay G.W., Shelmilt S.J.A., Rezaie P., and Cooper J.D. Glial activation spreads from specific cerebral foci precedes neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis (CLN6). Neurobiol. Dis. 20 (2005) 49-63
164. Kay G., Palmer D., Rezaie P., and Cooper J. Activation of non-neuronal cells within the prenatal developing brain of sheep with neuronal ceroid lipofuscinosis. Brain Pathol. 16 (2006) 110-116
165. Heine C., Tyynelä J., Cooper J.D., Palmer D.N., Elleder M., Kohlschütter A., and Braulke T. Enhanced expression of manganese-dependent superoxide dismutase in human and sheep CLN6 tissues. Biochem. J. 376 (2003) 369-376
166. Pears M., Salek R., Palmer D., Kay G., Mortishire-Smith R., and Griffin J. Metabolomic investigation of CLN6 neuronal ceroid lipofuscinosis in affected South Hampshire sheep. J. Neurosci. Res. 85 (2007) 3494-3504
167. Pears M.R., Cooper J.D., Mitchison H.M., Mortishire-Smith R.J., Pearce D.A., and Griffin J.L. High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J. Biol. Chem. 280 (2005) 42508-42514
168. Oswald M., Kay G., and Palmer D. Changes in GABAergic neuron distribution in situ and in neuron cultures in ovine (OCL6) Batten disease. Eur. J. Paediatr. Neurol. 5 Suppl A (2001) 135-142
169. Kasho V.N., Smirnova I.N., and Kaback H.R. Sequence alignment and homology threading reveals prokaryotic and eukaryotic proteins similar to lactose permease. J. Mol. Biol. 358 (2006) 1060-1070
170. Topcu M., Tan H., Yalnizoglu D., Usubutun A., Saatci I., Aynaci M., Anlar B., Topaloglu H., Turanli G., Kose G., and Aysun S. Evaluation of 36 patients from Turkey with neuronal ceroid lipofuscinosis: clinical, neurophysiological, neuroradiological and histopathologic studies. Turk. J. Pediatr. 46 (2004) 1-10
171. Ranta S., Zhang Y., and Ross B. The neuronal ceroid-lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8. Nat. Genet. 23 (1999) 233-236
172. Lonka L., Kyttala A., Ranta S., Jalanko A., and Lehesjoki A.E. The neuronal ceroid lipofuscinosis CLN8 membrane protein is a resident of the endoplasmic reticulum. Hum. Mol. Genet. 9 (2000) 1691-1697
173. Lonka L., Salonen T., Siintola E., Kopra O., Lehesjoki A.E., and Jalanko A. Localization of wild-type and mutant neuronal ceroid lipofuscinosis CLN8 proteins in non-neuronal and neuronal cells. J. Neurosci. Res. 76 (2004) 862-871
174. Winter E., and Ponting C.P. TRAM, LAG1 and CLN8: members of a novel family of lipid-sensing domains?. Trends Biochem. Sci. 27 (2002) 381-383
175. Riebeling C., Allegood J.C., Wang E., Merrill Jr. A.H., and Futerman A.H. Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J. Biol. Chem. 278 (2003) 43452-43459
176. Ranta S., Topcu M., Tegelberg S., Tan H., Üstübütün A., Saatci I., Dufke A., Enders H., Pohl K., Alembik Y., Mitchell W.A., Mole S.E., and Lehesjoki A.E. Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to northern epilepsy. Hum. Mutat. 23 (2004) 300-305
177. Cannelli N., Cassandrini D., Bertini E., Striano P., Fusco L., Caggero R., Specchio N., Biancheri R., Vigevano R., Bruno C., Simonati A., Zara F., and Santorelli F.M. Novel mutations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: another genetic hit in the Mediterranian. Neurogenetics 7 (2006) 111-117
178. Zelnik N., Mahajna M., Iancu T.C., Sharony R., and Zeigler M. A novel mutation of the CLn8 gene: is there a Mediterranian phenotype?. Pediatr. Neurol. 36 (2007) 411-413
179. Ranta S., and Lehesjoki A.E. Northern epilepsy, a new member of the NCL family. Neurol. Sci. 21 (2000) S43-S47
180. Lang A., Hirvasniemi A., and Siivola J. Neurophysiological findings in the northern epilepsy syndrome. Acta. Neurol. Scand. 95 (1997) 1-8
181. Hermansson M., Kakela R., Berghall M., Lehesjoki A.E., Somerharju P., and Lahtinen U. Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation. EPMR, brain: a case study. J. Neurochem. 95 (2005) 609-617
182. Messer A., Plummer J., Wong V., and Lavail M.M. Retinal degeneration in motor neuron degeneration (mnd) mutant mice. Exp Eye Res. 57 (1993) 637-641
183. Messer A., Plummer J., MacMillen M., and Frankel W. Genetics of primary and timing effects in the mnd mouse. Am. J. Med. Genet. 57 (1995) 361-364
184. Bertamini M., Marzani B., Guarneri R., Guarneri P., Bigini P., Mennini T., and Curti D. Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system. Eur. J. Neurosci. 16 (2002) 2291-2296
185. Vance J.E., Stone S.J., and Faust J.R. Abnormalities in mitochondria-associated membranes and phospholipid biosynthetic enzymes in the mnd/mnd mouse model of neuronal ceroid lipofuscinosis. Biochim. Biophys. Acta (BBA) - Lipids Lipid Metab. 1344 (1997) 286-299
186. Guarneri R., Russo D., Cascio C., D'Agostino S., Galizzi G., Bigini P., Mennini T., and Guarneri P. Retinal oxidation, apoptosis and age- and sex-differences in the mnd mutant mouse, a model of neuronal ceroid lipofuscinosis. Brain Res. 1014 (2004) 209-220
187. Battaglioli G., Martin D., Plummer J., and Messer A. Synaptosomal glutamate uptake declines progressively in the spinal cord of a mutant mouse with motor neuron disease. J. Neurochem. 60 (1993) 1567-1569
188. Mennini T., Bastone A., Crespi D., Comoletti D., and Manzoni C. Spinal cord GLT-1 glutamate transporter and blood glutamic acid alterations in motor neuron degeneration (Mnd) mice. J. Neurol. Sci. 157 (1998) 31-36
189. Mennini T., Bigini P., Ravizza T., Vezzani A., Calvaresi N., Tortarolo M., and Bendotti C. Expression of glutamate receptor subtypes in the spinal cord of control and mnd mice, a model of motor neuron disorder. J. Neurosci. Res. 70 (2002) 553-560
190. Katz M., Khan S., Awano T., Shahid S., Siakotos A., and Johnson G. A mutation in the CLN8 gene in English setter dogs with neuronal ceroid-lipofuscinosis. Biochem. Biophys. Res. Commun. 327 (2005) 541-547
191. Schulz A., Dhar S., Rylova S., Dbaibo G., Alroy J., Hagel C., Artacho I., Kohlschütter A., Lin S., and Boustany R.M. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann. Neurol. 56 (2004) 342-350
192. Guillas I., Kirchman P., Chuard R., Pfefferli M., Jiang J., Jazwinski S., and Conzelmann A. C26-CoA-dependent ceramide synthesis of Saccharomyces cerevisiae is operated by Lag1p and Lac1p. EMBO J. 20 (2001) 2655-2665
193. Schulz A., Mousallem T., Venkataramani M., Persaud-Sawin D.A., Zucker A., Luberto C., Bielawska A., Bielawski J., Holthuis J.C., Jazwinski S.M., Kozhaya L., Dbaibo G.S., and Boustany R.M. The CLN9 protein, a regulator of dihydroceramide synthase. J. Biol. Chem. 281 (2006) 279-2784
194. Gieselmann V., Hasilik A., and von Figura K. Processing of human cathepsin D in lysosomes in vitro. J. Biol. Chem. 260 (1985) 3215-3220
195. Dittmer F., Ulbrich E., Hafner A., Schmahl W., Meister T., Pohlmann R., and von Figura K. Alternative mechanisms for trafficking of lysosomal enzymes in mannose 6-phosphate receptor-deficient mice are cell type-specific. J. Cell. Sci. 112 (1999) 1591-1597
196. van Meel E., and Klumperman J. Imaging and imagination: understanding the endo-lysosomal system. Histochem. Cell Biol. 129 (2008) 253-266
197. Saftig P., Hetman M., Schmahl W., Weber K., Heine L., Mossmann H., Köster A., Hess B., Evers M., von Figura K., et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 14 (1995) 3599-3608
198. Gopalakrishnan M.M., Grosch H.W., Locatelli-Hoops S., Werth N., Smolenova E., Nettersheim M., Sandhoff K., and Hasilik A. Purified recombinant human prosaposin forms oligomers that bind procathepsin D and affect its autoactivation. Biochem. J. 383 (2004) 507-515
199. Kolter T., and Sandhoff K. Sphingolipid metabolism diseases. Biochim. Biophys. Acta 1758 (2006) 2057-2079
200. Berchem G.M., Gleizes M., Brouillet J.P., Vignon F., Garcia M., and Liaudet-Coopman E. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21 (2002) 5951-5955
201. Moss C., Villadangos J., and Watts C. Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing. Eur. J. Immunol. 35 (2005) 3442-3451
202. Haidar B., Kiss R., Sarov-Blat L., Brunet R., Harder C., McPherson R., and Yl M. Cathepsin D, a lysosomal protease, regulates ABCA1-mediated lipid efflux. J. Biol. Chem. 281 (2006) 39971-39981
203. Benes P., Vetvicka V., and Fusek M. Cathepsin D-many functions of one aspartic protease. Crit. Rev. Oncol. Hematol. 68 (2008) 12-28
204. Tyynelä J., Sohar I., Sleat D., Gin R., Donnelly R., Baumann M., Haltia M., and Lobel P. A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. EMBO J. 19 (2000) 2786-2792
205. Awano T., Katz M.L., O'Brien P.D., Taylor J.F., Evans J., Khan S., Sohar I., Lobel P., and Johnson G.S. A mutation in the cathepsin D gene (CTSD) in American Bulldogs with neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 87 (2006) 341-348
206. Shimizu T., Hayashi Y., Yamasaki R., Yamada J., Zhang J., Ukai K., Koike M., Mine K., von Figura K., Peters C., Saftig P., Fukuda T., Uchiyama Y., and Nakanishi H. Proteolytic degradation of glutamate decarboxylase mediates disinhibition of hippocampal CA3 pyramidal cells in cathepsin D-deficient mice. J. Neurochem. 94 (2005) 680-690
207. Koike M., Nakanishi H., Saftig P., Ezaki J., Isahara K., Ohsawa Y., Schulz-Schaeffer W., Watanabe T., Waguri S., Kametaka S., Shibata M., Yamamoto K., Kominami E., Peters C., von Figura K., and Uchiyama Y. Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J. Neurosci. 20 (2000) 6898-6906
208. Partanen S., Haapanen A., Kielar C., Pontikis C., Alexander N., Inkinen T., Saftig P., Gillingwater T., Cooper J., and Tyynelä J. Synaptic changes in the thalamocortical system of cathepsin D-deficient mice: a model of human congenital neuronal ceroid-lipofuscinosis. J. Neuropathol. Exp. Neurol. 67 (2008) 16-29
209. Koike M., Shibata M., Ohsawa Y., Nakanishi H., Koga T., Kametaka S., Waguri S., Momoi T., Kominami E., Peters C., Figura K., Saftig P., and Uchiyama Y. Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice. Mol. Cell. Neurosci. 22 (2003) 146-161
210. Shacka J., Klocke B., Young C., Shibata M., Olney J., Uchiyama Y., Saftig P., and Roth K. Cathepsin D deficiency induces persistent neurodegeneration in the absence of Bax-dependent apoptosis. J. Neurosci. 27 (2007) 2081-2090
211. Nakanishi H., Zhang J., Koike M., Nishioku T., Okamoto Y., Kominami E., von Figura K., Peters C., Yamamoto K., Saftig P., and Uchiyama Y. Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice. J. Neurosci. 21 (2001) 7526-7533
212. Partanen S., Storch S., Löffler H.-G., Hasilik A., Tyynelä J., and Braulke T. A replacement of the active-site aspartic acid residue 293 in mouse cathepsin D affects its intracellular stability, processing and transport in HEK-293 cells. Biochem. J. 369 (2003) 55-62
213. Myllykangas L., Tyynelä J., Page-McCaw A., Rubin G.M., Haltia M.J., and Feany M.B. Cathepsin D-deficient Drosophila recapitulate the key features of neuronal ceroid lipofuscinoses. Neurobiol. Dis. 19 (2005) 194-199
214. Brandt S., and Jentsch T. ClC-6 and ClC-7 are two novel broadly expressed members of the CLC chloride channel family. FEBS Lett. 377 (1995) 15-20
215. Kornak U., Kasper D., Bösl M., Kaiser E., Schweizer M., Schulz A., Friedrich W., Delling G., and Jentsch T. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104 (2001) 205-215
216. Kasper D., Planells-Cases R., Fuhrmann J., Scheel O., Zeitz O., Ruether K., Schmitt A., Poët M., Steinfeld R., Schweizer M., Kornak U., and Jentsch T. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J. 24 (2005) 1079-1091
217. Jentsch T.J. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit. Rev. Biochem. Mol. Biol. 43 (2008) 3-36
218. Stobrawa S.M., Breiderhoff T., Takamori S., Engel D., Schweizer M., Zdebik A.A., Bösl M.R., Ruethe K., Jahn H., Draguhn A., Jahn R., and Jentsch T.J. Disruption of ClC-3, a chloride channel expressed on synaptic vesicles, leads to a loss of the hippocampus. Neuron. 29 (2001) 185-196
219. Lange P., Wartosch L., Jentsch T., and Fuhrmann J. ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 440 (2006) 220-223
220. Graves A., Curran P., Smith C., and Mindell J. The Cl-/H+ antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature 453 (2008) 788-792
221. Frattini A., Pangrazio A., Susani L., Sobacchi C., Mirolo M., Abinun M., Andolina M., Flanagan A., Horwitz E., Mihci E., Notarangelo L., Ramenghi U., Teti A., Van Hove J., Vujic D., Young T., Albertini A., Orchard P., Vezzoni P., and Villa A. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J. Bone Miner. Res. 18 (2003) 1740-1747
222. Waguespack S., Hui S., Dimeglio L., and Econs M. Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation. J. Clin. Endocrinol. Metab. 92 (2007) 771-778
223. Conradi N.G., Uvebrant P., Hökegård K.H., Wahlström J., and Mellqvist L. First-trimester diagnosis of juvenile neuronal ceroid lipofuscinosis by demonstration of fingerprint inclusions in chorionic villi. Prenat. Diagn. 9 (1989) 283-287
224. Lake B.D., and Hall N.A. Immunolocalization studies of subunit c in late-infantile and juvenile Batten disease. J. Inherit. Metab. Dis. 16 (1993) 263-266
225. Scheel O., Zdebik A.A., Lourdel S., and Jentsch T.J. Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 436 (2005) 424-427
226. Yoshikawa M., Uchida S., Ezaki J., Rai T., Hayama A., Kobayashi K., Kida Y., Noda M., Koike M., Uchiyama Y., Marumo F., Kominami E., and Sasaki S. CLC-3 deficiency leads to phenotypes similar to human neuronal ceroid lipofuscinosis. Genes Cells 7 (2002) 597-605
227. Dickerson L.W., Bonthius D.J., Schutte B.C., Yang B., Barna T.J., Bailey M.C., Nehrke K., Williamson R.A., and Lamb F.S. Altered GABAergic function accompanies hippocampal degeneration in mice lacking ClC-3 voltage-gated chloride channels. Brain Res. 2958 (2002) 227-250
228. Poët M., Kornak U., Schweizer M., Zdebik A.A., Scheel O., Hoelter S., Wurst W., Schmitt A., Fuhrmann J.C., Planells-Cases R., Mole S.E., Hübner C.A., and Jentsch T.J. Lysosomal storage disease upon disruption of the neuronal chloride transport protein ClC-6. Proc. Natl. Acad. Sci. U. S. A. 102 (2006) 13854-13859